Samples taken from Marion Biotech Noida facility sent to RDTL, Chandigarh for testing
There have been reports from Uzbekistan concerning contaminated cough syrup Dok1 Max made by Indian company Marion Biotech, Noida, Uttar Pradesh
There have been reports from Uzbekistan concerning contaminated cough syrup Dok1 Max made by Indian company Marion Biotech, Noida, Uttar Pradesh
The new facility will be able to handle four times as many patients as the previous facility.
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Subscribe To Our Newsletter & Stay Updated